Literature DB >> 23908124

The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection.

Jason Grebely1, Kimberly Page, Rachel Sacks-Davis, Maarten Schim van der Loeff, Thomas M Rice, Julie Bruneau, Meghan D Morris, Behzad Hajarizadeh, Janaki Amin, Andrea L Cox, Arthur Y Kim, Barbara H McGovern, Janke Schinkel, Jacob George, Naglaa H Shoukry, Georg M Lauer, Lisa Maher, Andrew R Lloyd, Margaret Hellard, Gregory J Dore, Maria Prins.   

Abstract

UNLABELLED: Although 20%-40% of persons with acute hepatitis C virus (HCV) infection demonstrate spontaneous clearance, the time course and factors associated with clearance remain poorly understood. We investigated the time to spontaneous clearance and predictors among participants with acute HCV using Cox proportional hazards analyses. Data for this analysis were drawn from an international collaboration of nine prospective cohorts evaluating outcomes after acute HCV infection. Among 632 participants with acute HCV, 35% were female, 82% were Caucasian, 49% had interleukin-28 (IL28)B CC genotype (rs12979860), 96% had injected drugs ever, 47% were infected with HCV genotype 1, and 7% had human immunodeficiency virus (HIV) coinfection. Twenty-eight percent were HCV antibody negative/RNA positive at the time of acute HCV detection (early acute HCV). During follow-up, spontaneous clearance occurred in 173 of 632, and at 1 year after infection, 25% (95% confidence interval [CI]: 21, 29) had cleared virus. Among those with clearance, the median time to clearance was 16.5 weeks (IQR: 10.5, 33.4), with 34%, 67%, and 83% demonstrating clearance at 3, 6, and 12 months. Adjusting for age, factors independently associated with time to spontaneous clearance included female sex (adjusted hazards ratio [AHR]: 2.16; 95% CI: 1.48, 3.18), IL28B CC genotype (versus CT/TT; AHR, 2.26; 95% CI: 1.52, 3.34), and HCV genotype 1 (versus non-genotype 1; AHR: 1.56; 95% CI: 1.06, 2.30). The effect of IL28B genotype and HCV genotype on spontaneous clearance was greater among females, compared to males.
CONCLUSIONS: Female sex, favorable IL28B genotype, and HCV genotype 1 are independent predictors of spontaneous clearance. Further research is required to elucidate the observed sex-based differences in HCV control.
© 2013 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23908124      PMCID: PMC3972017          DOI: 10.1002/hep.26639

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  31 in total

Review 1.  Sex hormones and the immune response in humans.

Authors:  Annechien Bouman; Maas Jan Heineman; Marijke M Faas
Journal:  Hum Reprod Update       Date:  2005-04-07       Impact factor: 15.610

Review 2.  Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies.

Authors:  J M Micallef; J M Kaldor; G J Dore
Journal:  J Viral Hepat       Date:  2006-01       Impact factor: 3.728

3.  Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia.

Authors:  Mingdong Zhang; Philip S Rosenberg; Deborah L Brown; Liliana Preiss; Barbara A Konkle; M Elaine Eyster; James J Goedert
Journal:  Blood       Date:  2005-10-04       Impact factor: 22.113

4.  Prospective evaluation of community-acquired acute-phase hepatitis C virus infection.

Authors:  Andrea L Cox; Dale M Netski; Timothy Mosbruger; Susan G Sherman; Steffanie Strathdee; Danielle Ompad; David Vlahov; David Chien; Venkatakrishna Shyamala; Stuart C Ray; David L Thomas
Journal:  Clin Infect Dis       Date:  2005-03-03       Impact factor: 9.079

5.  Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy.

Authors:  T Santantonio; E Medda; C Ferrari; P Fabris; G Cariti; M Massari; S Babudieri; M Toti; R Francavilla; F Ancarani; G Antonucci; G Scotto; V Di Marco; G Pastore; T Stroffolini
Journal:  Clin Infect Dis       Date:  2006-09-27       Impact factor: 9.079

6.  Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type?

Authors:  H E Harris; K P Eldridge; S Harbour; G Alexander; C-G Teo; M E Ramsay
Journal:  J Viral Hepat       Date:  2007-03       Impact factor: 3.728

7.  Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy.

Authors:  S C Ray; Y M Wang; O Laeyendecker; J R Ticehurst; S A Villano; D L Thomas
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

8.  Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics.

Authors:  Tobias Marcello; Arash Grakoui; Giovanna Barba-Spaeth; Erica S Machlin; Sergei V Kotenko; Margaret R MacDonald; Charles M Rice
Journal:  Gastroenterology       Date:  2006-10-01       Impact factor: 22.682

9.  Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance.

Authors:  Chia C Wang; Elizabeth Krantz; Jared Klarquist; Meighan Krows; Lanamarie McBride; Edward P Scott; Thomas Shaw-Stiffel; Scott J Weston; Hanne Thiede; Anna Wald; Hugo R Rosen
Journal:  J Infect Dis       Date:  2007-10-31       Impact factor: 5.226

10.  Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates.

Authors:  Kimberly Page-Shafer; Brandee L Pappalardo; Leslie H Tobler; Bruce H Phelps; Brian R Edlin; Andrew R Moss; Teresa L Wright; David J Wright; Thomas R O'Brien; Sally Caglioti; Michael P Busch
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

View more
  144 in total

Review 1.  Sex differences in immune responses to infectious diseases.

Authors:  Julia Fischer; Norma Jung; Nirmal Robinson; Clara Lehmann
Journal:  Infection       Date:  2015-05-09       Impact factor: 3.553

2.  Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.

Authors: 
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

3.  Genomic variability of within-host hepatitis C variants in acute infection.

Authors:  Chaturaka Rodrigo; Preston Leung; Andrew R Lloyd; Rowena A Bull; Fabio Luciani; Jason Grebely; Gregory J Dore; Tanya Applegate; Kimberly Page; Julie Bruneau; Andrea L Cox; William Osburn; Arthur Y Kim; Naglaa H Shoukry; Georg M Lauer; Lisa Maher; Janke Schinkel; Maria Prins; Margaret Hellard; Auda A Eltahla
Journal:  J Viral Hepat       Date:  2019-01-22       Impact factor: 3.728

4.  Interferon λ 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types.

Authors:  François M J Lamoury; Sofia Bartlett; Brendan Jacka; Behzad Hajarizadeh; Jason Grebely; Gail V Matthews; Gregory J Dore; Tanya L Applegate
Journal:  J Mol Diagn       Date:  2015-07-04       Impact factor: 5.568

5.  Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs.

Authors:  Jason Grebely; Sarah Larney; Amy Peacock; Samantha Colledge; Janni Leung; Matthew Hickman; Peter Vickerman; Sarah Blach; Evan B Cunningham; Kostyantyn Dumchev; Michael Lynskey; Jack Stone; Adam Trickey; Homie Razavi; Richard P Mattick; Michael Farrell; Gregory J Dore; Louisa Degenhardt
Journal:  Addiction       Date:  2018-08-28       Impact factor: 6.526

6.  Role of genetic polymorphisms in hepatitis C virus chronic infection.

Authors:  Nicola Coppola; Mariantonietta Pisaturo; Caterina Sagnelli; Lorenzo Onorato; Evangelista Sagnelli
Journal:  World J Clin Cases       Date:  2015-09-16       Impact factor: 1.337

7.  Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population.

Authors:  Julia L Marcus; Leo B Hurley; Scott Chamberland; Jamila H Champsi; Laura C Gittleman; Daniel G Korn; Jennifer B Lai; Jennifer O Lam; Mary Pat Pauly; Charles P Quesenberry; Joanna Ready; Varun Saxena; Suk I Seo; David J Witt; Michael J Silverberg
Journal:  Public Health Rep       Date:  2018-05-11       Impact factor: 2.792

8.  Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.

Authors:  Matthew J Akiyama; Charles M Cleland; John A Lizcano; Peter Cherutich; Ann E Kurth
Journal:  Lancet Infect Dis       Date:  2019-09-17       Impact factor: 25.071

Review 9.  Individualization of chronic hepatitis C treatment according to the host characteristics.

Authors:  Nikolaos K Gatselis; Kalliopi Zachou; Asterios Saitis; Maria Samara; George N Dalekos
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

10.  Recommendations for the management of hepatitis C virus infection among people who inject drugs.

Authors:  Jason Grebely; Geert Robaeys; Philip Bruggmann; Alessio Aghemo; Markus Backmund; Julie Bruneau; Jude Byrne; Olav Dalgard; Jordan J Feld; Margaret Hellard; Matthew Hickman; Achim Kautz; Alain Litwin; Andrew R Lloyd; Stefan Mauss; Maria Prins; Tracy Swan; Martin Schaefer; Lynn E Taylor; Gregory J Dore
Journal:  Int J Drug Policy       Date:  2015-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.